Allogene ‘off-the-shelf’ CAR-T for leukemia shows high response rate at ASH

The company presented Phase I data from its study of allogeneic CAR-T UCART19, as well as preclinical data on a BCMA CAR-T for multiple myeloma.

Article Source: Allogene ‘off-the-shelf’ CAR-T for leukemia shows high response rate at ASH.